Findings showed 30% of patients in the ponatinib arm achieved MRD-negative complete response rate at the end of the induction phase vs 12% of those in the imatinib arm. The Food and Drug ...
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec[1] Data demonstrated higher rates of early and deeper ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- After receiving a priority review, Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug ...
Clearance of circulating leukemic blasts during induction therapy to predict treatment response regardless of cytogenetic risk or age in adult acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results